| Literature DB >> 19022315 |
Jian Yan1, Dawn K Reichenbach, Natasha Corbitt, David A Hokey, Mathura P Ramanathan, Kibwei A McKinney, David B Weiner, Duane Sewell.
Abstract
Human papillomavirus type 16 (HPV-16) infection is associated with a majority of cervical cancers and a significant proportion of head and neck cancers. Here, we describe a novel-engineered DNA vaccine that encodes a HPV-16 consensus E6/E7 fusion gene (pConE6E7) with the goal of increasing its antitumor cellular immunity. Compared to an early stage HPV-16 E7 DNA vaccine (pE7), this construct was up to five times more potent in driving E7-specific cellular immune responses. Prophylactic administration of this vaccine resulted in 100% protection against HPV E6 and E7-expressing tumors. Therapeutic studies indicated that vaccination with pConE6E7 prevented or delayed the growth of tumors. Moreover, immunization with pConE6E7 could also partially overcome immune tolerance in E6/E7 transgenic mice. Such DNA immunogens are interesting candidates for further study to investigate mechanisms of tumor immune rejection in vivo.Entities:
Mesh：
Substances：
Year: 2008 PMID： 19022315 PMCID： PMC4477831 DOI： 10.1016/j.vaccine.2008.10.078
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641